Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Total Liabilities
Everything the company owes to creditors and other parties.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 38.9% from a year ago
Total liabilities stood at $10.48B at the end of Q3 FY2026, up 38.9% from a year earlier and up 46.0% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Total liabilities amounted to 32.0% of total assets at the end of Q3 FY2026, up 1.7 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +38.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.48B USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- +22.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.48B | +22.1% |
| FY2024 | 2024-12-31 | 6.12B | +18.9% |
| FY2023 | 2023-12-31 | 5.15B | +21.5% |
| FY2022 | 2022-12-31 | 4.24B | +27.2% |
| FY2021 | 2021-12-31 | 3.33B | — |
Total Liabilities vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's Sep 2026 total liabilities of $10.48B is the 2nd highest of the 11 companies compared; the peer median is $2.1B.
- Its year-over-year change of +38.9% is the 3rd highest of 11, against a peer median of +12.3%.
- Total liabilities amounts to 32.0% of total assets for VRTX, versus a peer median of 64.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.31T | +340892.5% | -5.3% | 45.9% | |
| Sep 2026 | $10.48B | +38.9% | +20.8% | 32.0% | |
| Jun 2026 | $4.2B | -2.6% | +4.1% | 75.6% | |
| Jun 2026 | $3.72B | +30.2% | +17.3% | 305.9% | |
| Jun 2026 | $3.42B | +20.2% | +14.8% | 105.1% | |
| Sep 2026 | $2.52B | +4.3% | +15.7% | 86.5% | |
| Mar 2026 | $1.67B | -27.9% | -7.0% | 52.7% | |
| Mar 2026 | $1.53B | +31.4% | +10.4% | 117.7% | |
| Sep 2026 | $908.34M | +175.8% | -2.2% | 35.5% | |
| Jun 2026 | $319.19M | -7.3% | -26.4% | 23.0% | |
| Mar 2026 | $137.84M | -33.2% | -15.7% | 18.2% | |
| Peer median (excluding VRTX) | $2.1B | +12.3% | +0.9% | 64.1% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.8B | 10.5B | 10.37B | 4.57B | 5.09B |
| Short-term Investments | 729.9M | 274.5M | 849.2M | 1.55B | 1.52B |
| Net Receivables | 1.14B | 1.44B | 1.56B | 1.61B | 2.05B |
| Inventory | 353.1M | 460.6M | 738.8M | 1.21B | 1.69B |
| Other Current Assets | 103.7M | 121.9M | 86.1M | 206.5M | 748.6M |
| Total Current Assets | 9.56B | 13.23B | 14.14B | 9.6B | 11.2B |
| Property, Plant & Equipment (Net) | 1.42B | 1.46B | 1.45B | 2.58B | 3.08B |
| Goodwill | 1B | 1.09B | 1.09B | 1.09B | 1.09B |
| Intangible Assets | 400M | 603.6M | 839.9M | 825.9M | 424.2M |
| Long-term Investments | 0 | 112.2M | 2.5B | 5.11B | 5.81B |
| Tax Assets | 934.5M | 1.25B | 1.81B | 2.33B | 3.4B |
| Other Non-current Assets | 110.8M | 409.6M | 895.3M | 999.3M | 1.14B |
| Total Non-current Assets | 3.87B | 4.92B | 8.59B | 12.94B | 14.94B |
| Total Assets | 13.43B | 18.15B | 22.73B | 22.53B | 26.14B |
| Account Payables | 195M | 303.9M | 364.9M | 413M | 461.7M |
| Short-term Debt | 0 | 0 | 0 | 92.3M | 82.8M |
| Tax Payables | 211.3M | 123.3M | 99.5M | 161.1M | 0 |
| Deferred Revenue | 171.7M | 159.6M | 170.3M | 206.8M | 171.8M |
| Other Current Liabilities | 16.5M | 62.5M | 50.7M | 2.5B | 2.75B |
| Total Current Liabilities | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.85B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.31B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 303.3M | 685.8M | 877.7M | 901.8M | (1.49B) |
| Total Non-current Liabilities | 1.19B | 1.5B | 1.6B | 2.56B | 3.62B |
| Total Liabilities | 3.33B | 4.24B | 5.15B | 6.12B | 7.48B |
| Common Stock | 2.5M | 2.6M | 2.6M | 2.6M | 2.5M |
| Retained Earnings | 3.2B | 6.52B | 10.14B | 9.61B | 13.56B |
| Accumulated OCI | 15.9M | 800K | (14.3M) | 127.8M | (15.9M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.1B | 13.91B | 17.58B | 16.41B | 18.67B |
| Total Debt | 967.4M | 899.7M | 808.4M | 1.75B | 3.88B |
| Net Debt | (5.83B) | (9.6B) | (9.56B) | (2.82B) | (1.21B) |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.